H ypertensive disorders in pregnancy are the most common medical complications of pregnancy, affecting 5% to 10% of pregnancies. It has been long believed that all the problems of gestational hypertension get solved within 6 weeks postpartum. However, gestational hypertension, and preeclampsia in particular, has been found to be associated with an increased risk of developing hypertension, stroke, coronary heart disease, and venous thromboembolism in later life. 1 A recent systematic review and meta-analysis 2 of 22 studies including >258 000 women with preeclampsia found preeclampsia to be associated with a 4-fold increase in incident heart failure and a 2-fold increased risk in coronary heart disease, stroke, and cardiovascular death. Preexisting hypertension is associated with an increased risk of developing preeclampsia, which may complicate %25% of cases. There is now convincing evidence that this risk can be substantially reduced by using low-dose acetylsalicylic acid (100-150 mg, aspirin). The new crucial point is that low-dose aspirin should be initiated from week 12 and continued to weeks 36 to 37. 3 In this issue of the Journal of the American Heart Association (JAHA), there are 2 articles addressing late cardiovascular complications of hypertensive pregnancies. 4, 5 A nested-case control study of 7566 women who had live birth or stillbirth delivery in Olmsted County, Minnesota, between 1976 and 1982 found that women experiencing hypertensive pregnancy disorders had a greater chance of developing atrial fibrillation compared with normotensive controls. 4 This relationship could have been, at least partially, mediated by associated obesity and hypertension. Atrial fibrillation was diagnosed 31AE8 years after the first pregnancy in cases and 30AE8 years after the first pregnancy in controls.
It is the first study directly evaluating the relationship between hypertensive pregnancy disorders and atrial fibrillation. The advantage of this study is that cases and controls come from the same population, Olmsted County.
On the other hand, there are also some study limitations, such as its retrospective design and no standardization of blood pressure (BP) measurement. However, the Olmsted County population is almost 100% white and all women included in the study had at least high school level education. This population is definitely not representative of the United States. All hypertensive disorders in pregnancy, and preeclampsia in particular, are more common in blacks.
The Riise et al 5 also suggest that gestational hypertension and preeclampsia should be analyzed separately in future studies. Similar to the case-control study from Olmsted County, there is no standardization of BP measurement. Moreover, the Medical Birth Registry of Norway uses a different definition of gestational hypertension (ie, hypertension occurring after 20 weeks of gestation defined as systolic BP ≥140 mm Hg and/or diastolic BP ≥90 mm Hg or an increase >15 mm Hg from BP measured before gestational week 20).
Despite the limitations of and differences between both studies, they convincingly show the increased risk of late CVD after hypertensive pregnancies. More important, both studies show the significance of gestational hypertension, whereas previous studies suggested the risk was particularly increased in preeclampsia.
Thus, both studies clearly highlight the need for establishing regular follow-up of women with hypertensive pregnancy disorders. 6 The 2011 American Heart Association updated guidelines for the prevention of CVD in women 7 stated that pregnancy provides a unique opportunity to estimate a woman's lifetime risk. It was also suggested that preeclampsia may be an early indicator of CVD risk. The risk of preeclampsia and pregnancy-induced hypertension was not recognized in Europe until the publication of the 2016 European Guidelines on CVD prevention in clinical practice, 8 suggesting consideration of periodic screening for hypertension and diabetes mellitus (IIa class of recommendation, B level of evidence). In women with a history of premature birth, the recommendation is that periodic screening for hypertension and diabetes mellitus may be considered (IIb class of recommendation, B level of evidence). Despite the agreement of both guidelines 7, 8 that pregnancy may represent a unique stress test to identify women with a future risk of developing CVD, no systematic follow-up has been established to date. Women with hypertension in pregnancy are rarely told about their future risk of subsequent CVD, including hypertension; they are reluctant to come for a checkup, pretending they are fully occupied by care of their infants.
In conclusion, pregnancy offers a unique window for identification of women at risk of future CVD. Efforts should be made to establish specialized clinics to monitor women postpartum to reduce the burden of future CVD.
